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Abstract 
Introduction: The goal of this study was to evaluate whether any characteristics that are evident at presentation for urgent medical attention 
could be used to differentiate cases of H5N1 in the absence of viral testing.   
Methodology: Information about exposure to poultry, clinical signs and symptoms, treatments, and outcomes was abstracted from existing 
data in the global avian influenza registry (www.avianfluregistry.org) using standardized data collection tools for documented and possible 
cases of H5N1 infection who presented for medical attention between 2005-2011 during known H5N1 outbreaks in Azerbaijan, Indonesia, 
Pakistan and Turkey.   
Results: Demography, exposure to poultry, and presenting symptoms were compared, with only the common symptoms of fever and 
headache presenting significantly more frequently in confirmed H5N1 cases than in possible cases. Reported exposure to  infected humans 
was also more common in confirmed cases. In contrast, unexplained respiratory illness, sore throat, excess sputum production, and rhinorrhea 
were more frequent in possible cases. Overall, oseltamivir treatment showed a survival benefit, with the greatest benefit shown in H5N1 
cases who were treated within two days of symptom onset (51% reduction in case fatality). 
Conclusion: Since prompt treatment with antivirals conferred a strong survival benefit for H5N1 cases, presumptive antiviral treatment 
should be considered for all possible cases presenting during an outbreak of H5N1 as a potentially life-saving measure.   
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Introduction 
The highly pathogenic avian influenza virus of 
subtype H5N1 remains prevalent in many countries, 
causing infections and deaths. Case fatality rates have 
been over 80% in Indonesia [1,2] and 59% overall, 
with outbreaks continuing to be reported largely in 
Egypt and Indonesia [3]. The H5N1 virus continues to 
mutate, with on-going concern about its potential to 
become more highly pathogenic and more easily 
transmissible [4,5]. Although the World Health 
Organization (WHO) provides counts of laboratory- 
confirmed cases of influenza A/H5N1, cases that are 
tested and identified represent only a fraction of the 
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total cases, and little is known about them collectively, 
aside from survival [6].   
Once an outbreak has started, medical care 
providers are confronted with a range of patients 
including true cases and possible cases who present for 
medical attention. Test results are rarely immediately 
available after presentation for medical care, and when 
available, may be positive, negative or have 
indeterminate results. Clinicians are often obliged to 
formulate treatment plans based upon presumptive 
diagnoses. The goal of this study was to describe the 
characteristics of confirmed cases, to compare them 
with possible cases who presented for medical care 
around the same time and in the same country, and to 
evaluate antiviral treatment effectiveness in both 
groups. Possible cases included those who presented 
for medical attention during a confirmed local 
outbreak through the same medical systems as did true 
cases, but who tested negative for H5N1, had 
indeterminate results, were never tested, or died before 
testing. 
 
Methodology 
The Avian Flu Registry 
(www.avianfluregistry.org) is an international patient 
registry for human cases of influenza A (H5N1). All 
cases were identified through record systems in 
regions with known outbreaks of H5N1 between 1997 
and 2011. Information about exposure to poultry, 
clinical signs and symptoms, treatments, and outcomes 
were collected in a web-enabled database. Data were 
abstracted from clinical records, published case series 
and governmental agency reports using a standardized 
data collection form. Avian exposure was classified as 
“in the vicinity of live poultry” and where available, 
direct or indirect contact with sick or dead poultry or 
wild birds was noted. The registry methods for case 
acquisition, data collection, and institutional review 
and approval are fully described elsewhere in detail 
[7,8]. 
The registry classifies cases according to certainty 
of diagnosis, with confirmed and possible cases used 
for these analyses. These categories were adapted from 
the WHO classification scheme [9] based on practical 
considerations from field experience and differ from 
the roughly equivalent WHO categories in a few 
important ways. The WHO classification scheme 
begins with suspected cases who had exposure to 
poultry or wild birds or infected persons. Possible 
cases have had exposure and also have infiltrates or 
evidence of an acute pneumonia or who were linked in 
time and place and exposure but died before testing 
could be performed. Confirmed cases met all the 
criteria for a suspected or probable case and had a 
positive laboratory confirmation of H5N1 from an 
influenza laboratory whose avian influenza or human 
pandemic influenza test results are accepted by WHO 
as confirmatory. The registry’s confirmed cases are 
based on any laboratory report confirming infection 
with influenza A/H5N1, and is not restricted to reports 
from WHO reference laboratories. The definitions of 
influenza-related symptoms were broadened for the 
registry to accommodate practical application to these 
observational data. For example, the registry records a 
case as having had a fever if the patient record 
indicated “fever” but the actual body temperature was 
not available. In addition to symptoms used by the 
WHO (acute pneumonia on chest radiograph plus 
evidence of respiratory failure), gastrointestinal, and 
both upper and lower respiratory symptoms are 
recognized here as symptomatic, since these 
characteristics were noted in outbreaks of confirmed 
cases. Further, “close contact” was defined broadly 
based on available data. For example, presence of an 
infected family member in the household was an 
acceptable proxy for close contact, in contrast to the 
WHO definition of being within one meter of an 
infected person. Possible cases include people who 
presented for medical attention during known 
outbreaks of H5N1 and were thought to be true cases, 
but for whom confirmation of infection with H5N1 
was not documented (including negative and 
interdeterminate laboratory reports). 
As of April 30, 2012, the registry contained 647 
cases from 12 countries that were reported as H5N1 
(“all cases”), including 407 cases confirmed as 
influenza A (H5N1). To minimize differences in data 
availability by country, this analysis is restricted to 
cases from countries that reported both confirmed and 
possible cases of H5N1. Nineteen possible cases were 
excluded because data were missing for age, gender or 
outcome. Four countries met the criteria for inclusion: 
Azerbaijan (9 confirmed, 8 possible), Indonesia (127 
confirmed, 132 possible), Pakistan (4 confirmed, 7 
possible) and Turkey (13 confirmed, 53 possible), 
yielding 353 cases: 153 confirmed and 200 possible 
cases, all occurring between 2005 and 2011. 
The characteristics of confirmed and possible 
cases were compared by examining differences in 
demography, clinical presentation and treatment 
effects. Differences in the prevalence of symptoms at 
presentation for medical care were compared using 
Fisher’s Exact test. Differences in treatment with 
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oseltamivir and survival were compared using the Chi-
square test for statistical significance. 
Survival by timing of treatment initiation was 
analyzed using 2x2 tables, with relative risks used to 
describe the risk of death in the treated patients 
compared with the same risk in untreated patients, 
with probability determined by use of a Fisher’s exact 
test. A delayed cohort entry strategy was used, with 
cases eligible to be included in the risk calculation for 
each treatment interval only if they had presented for 
medical care by the first day of the interval. Statistical 
significance was determined with α set at .05. All 
analyses were conducted using SAS v. 9.2 (SAS 
Institute, Cary, USA).  
 
Results 
Of 153 confirmed cases, 44.4% were male, with a 
median age of 17.0 years (range 1.5-67.0). In contrast, 
57.5% of 200 possible cases were male, with a median 
age of 13.0 years (range 0.4, 80.0). True cases were 
more likely than possible cases to have had direct 
contact with another confirmed case. Exposure to sick 
or dead poultry or wild birds was not a reliable aid for 
recognizing true cases (Table 1). 
Possible cases were more likely to present for 
medical attention at an emergency room (45.0% v. 
28.1%, respectively) and presented for medical care 
later than true cases (median of 2 v 0 days after 
symptom onset). Possible cases were hospitalized 
more quickly after symptom onset than confirmed 
cases (3 v 6 days), had viral testing sooner (3 v 7 
days), and had antiviral treatments initiated much 
more quickly (3 v 7 days) than confirmed cases. 
Confirmed cases had a substantially higher case 
fatality rate (79.1% v. 12.0%, p<.01) (Figure 1). 
 
The prevalence of symptoms at presentation for 
confirmed and possible cases are displayed in Table 2. 
Confirmed cases were more likely to present with 
fever (87.8% v 76.8%, p = 0.01) and headache (43.5% 
v 29.5%, p = 0.05). Tachypnea, a potential warning 
sign for clinicians, was also frequent in both 
confirmed and possible cases (32.5% v 25.6%, p = 
0.22.) In contrast, possible cases were more likely to 
have unexplained respiratory illnesses (82.8% v. 
65.7%, p < 0.01); sore throat or pharyngitis (62.4% v 
44.1%, p < 0.01), excessive sputum production (37.8% 
v 4.4%, p < 0.01) and rhinorrhea (29.1% v. 11.2%, p < 
0.01). 
  
Table 1: Exposure to poultry, wild birds and infected humans 
Exposure 
Cases  
Confirmed (N =153) Possible (N = 200) p-value 
n (%)a n (%)a  
Direct contact with sick or dead poultry 61/153 (39.9%) 98/200 (49.0%) 0.09 
Indirect contact with sick or dead poultry 33/153 (21.6%) 89/200 (44.5%) < 0.01 
Direct contact with sick or dead wild birds  3/153 (2.0%) 5/200 (2.5%) 1.00 
Indirect contact with sick or dead wild birds 6/153 (3.9%) 3/200 (1.5%) 0.18b 
In the vicinity of live poultry 55/153 (36.0%) 37/200 (18.5%) < 0.01 
Contact with a confirmed human case 29/153 (19.0%) 19/200 (9.5%) 0.01 
aMultiple exposures could be reported for a single case; categories are not mutually exclusive: bFisher’s exact test. 
Figure 1: Case fatality rate in confirmed and possible cases  
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  Table 2: Prevalence of symptoms at presentation for confirmed and possible cases 
 
 
Symptom at presentation 
Cases  
Confirmed (N=153) Possible (N=200) p-value 
n (%)a n (%)a  
Fever 122/139 (87.8%) 152/198 (76.8%) 0.01 
Unexplained respiratory illness with cough, 
shortness of breath or difficulty breathing 
92/140 (65.7%) 164/198 (82.8%) < 0.01 
Tachypnea 38/117 (32.5%) 40/156 (25.6%) 0.22 
Abnormal breath sounds 10/61 (16.4%) 33/129 (25.6%) 0.16 
Sore throat/pharyngitis 41/93 (44.1%) 108/173 (62.4%) < 0.01 
Cyanosis 4/74 (5.4%) 3/137 (2.2%) 0.24a 
Excessive sputum production 3/68 (4.4%) 48/127 (37.8%) < 0.01 
Rhinorrhea 10/89 (11.2%) 48/165 (29.1%) < 0.01 
Diarrhea 15/97 (15.5%) 19/180 (10.6%) 0.24 
Abdominal pain 20/89 (22.5%) 26/163 (16.0%) 0.20 
Vomiting 19/99 (19.2%) 22/177 (12.4%) 0.13 
Headache 40/92 (43.5%) 28/95 (29.5%) 0.05 
Fatigue or malaise 23/92 (25.0%) 24/108 (22.2%) 0.64 
Myalgia 11/67 (16.4%) 21/92 (22.8%) 0.32 
Neurologic involvement 2/70 (2.9%) 3/129 (2.3%) 1.00a 
Psychiatric 2/59 (3.4%) 1/121 (0.8%) 0.25a 
Bleeding gums and/or nose 4/97 (4.1%) 9/185 (4.9%) 1.00a 
Enlarged liver 1/60 (1.7%) 2/138 (1.5%) 1.00a 
Conjunctivitis 2/74 (2.7%) 5/169 (3.0%) 1.00a 
a% =(no. patients with symptom/no. patients for whom presence or absence of symptom was recorded)*100. 
bFisher’s exact Test. 
 
 
 
 
Table 3: Relative risk of survival for treated vs. untreated patients by time from symptom onset to oseltamivir treatment 
From symptom  
onset to treatment 
initiation 
 
Oseltamivir treated 
survived/total (%) 
No antiviral 
survived/total 
(%) 
Difference  
in %  
Survived 
 
Relative 
Risk 
 
95% 
CI 
 
 
P value 
Confirmed cases (N = 153)  
0-2 days 5/8(63) 11/97 (11) 0.51 5.51 2.54, 11.94 0.002 
3-5 days 6/18 (33) 13/97 (13) 0.20 2.49 1.09, 5.68 0.076 
6-8 days 2/22 (09) 13/76 (17) -0.08 0.53 0.13, 2.18 0.509 
9-11 days 1/14 (07) 12/42 (29) -0.21 0.25 0.04, 1.75 0.149 
≥12 days 0/1 (0) 12/21 (57) -0.57 0.00 NA 0.455 
Possible cases (N=200) 
0-2 days 43/46 (93) 70/79 (89) 0.05 1.05 0.95, 1.18 0.533 
3-5 days 50/50 (100) 69/79 (87) 0.13 1.14 1.05, 1.25 0.007 
6-8 days 7/10 (70) 69/76 (91) -0.21 0.77 0.51, 1.16 0.088 
9-11 days 3/5 (60) 67/72 (93) -0.33 0.64 0.31, 1.32 0.063 
≥12 days 2/4 (50) 66/69 (96) -0.46 0.52 0.20, 1.39 0.022 
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A larger proportion of possible cases were treated 
with oseltamivir (60.5% v. 47.1% respectively). 
Overall, oseltamivir treatment showed a benefit, with a 
tripling in the survival benefit in confirmed cases 
compared with possible cases (a 10.4% reduction in 
case fatality for confirmed cases versus a 3.2% 
reduction in possible cases, p < 0.01). The CFR in 
untreated cases was significantly higher (p < 0.01) in 
confirmed cases compared to possible cases (84.0% v 
13.9%). The greatest benefit is seen for confirmed 
cases treated with oseltamivir within two days of 
symptom onset (RR of survival = 5.51, 95% CI 2.54-
11.94, p = 0.002) with a benefit of treatment still 
evident when treatment was initiated up to five days 
after symptom onset (RR=2.46, 95% CI 1.09-5.68, p = 
0.076) (Table 3). In possible cases, however, the 
benefit of early treatment is not evident (RR of 
survival when treated 0-2 days after symptom onset 
=1.05, CI 0.95, 1.18). 
 
Discussion 
We undertook this study to examine whether any 
symptoms at presentation for medical care or avian 
exposure would differentiate true cases from possible 
cases occurring during the time of a confirmed H5N1 
outbreak, and to understand treatment effectiveness for 
these two groups. Recognizing the limitations of 
retrospective analyses which depend on the 
widespread availability of reliable clinical and 
outcome data from many countries, it is also worth 
nothing that the WHO definition of confirmed H5N1 
may be overly restrictive since many cases with 
documented H5N1 infection in this registry had 
symptoms that were different from the WHO 
definition. Nonetheless, not surprisingly, the mortality 
among true H5N1 cases was much higher than 
possible cases (79.1% v. 12.0%). This marked 
difference in mortality appears unrelated to medical 
care, since it appears that once a H5N1 outbreak has 
been confirmed, possible cases present directly to 
emergency care facilities and are hospitalized and 
treated quickly, most likely due to increased 
awareness. 
Direct or indirect contact with sick or dead poultry 
or wild birds did not serve to differentiate true and 
possible cases. Indirect exposure to sick or dead 
poultry was more common in possible cases, most 
likely reflecting the fact that these suspected cases 
occurred in regions where outbreaks were occurring. 
True cases were more likely to have reported contact 
with another confirmed case. 
The available data on symptoms at presentation 
indicate few differences between true and possible 
cases. The largest differentiator for true cases was a 
47.4% increase in the rate of headache. Even classic 
warning signs such as tachypnea and cyanosis gave no 
guide to etiology. In contrast, possible cases were 8.6 
times as likely to present with excessive sputum 
production (37.8% v. 4.4%) and 2.6 times as likely to 
present with rhinorrhea (29.1% v. 11.2%) as true 
cases. It is worth noting that rhinorrhea at presentation 
should not be excluded in the differential diagnosis of 
H5N1, since we have shown that rhinorrhea at 
presentation for true H5N1 infection in children aged 5 
years or younger is associated with improved survival 
[10]. 
Oseltamivir showed substantial effectiveness for 
H5N1, but not for ILI. Further, cases who survived at 
least 6 days from symptom onset without having been 
treated with an antiviral did not benefit from delayed 
initiation of oseltamivir. The low survival rates shown 
when oseltamivir is initiated more than a week or so 
after symptom onset for both confirmed and possible 
cases may reflect a last-ditch treatment in situations 
where death is imminent, but also may simply be an 
artifact caused by small numbers of cases. Thus these 
findings provide empirical evidence for the benefits of 
even delayed initiation of antiviral treatment for 
confirmed cases, a notion that was posed in 2005 [11] 
but not confirmed until 2010 [4].     
Examination of the times from symptom onset to 
various interventions reveals that in an outbreak, cases 
that present early in the outbreak’s course are unlikely 
to be immediately recognized, and are consequently 
disadvantaged by delays in diagnosis and initiation of 
appropriate antiviral therapy, with the lack of clinical 
differentiators to signal true H5N1 infection further 
compounding the difficulties clinicians face [12]. It is 
evident that oseltamivir confers a survival benefit for 
true cases of H5N1, and when confronted with cases 
with influenza-like symptoms during an outbreak and 
in the absence of immediate virological testing, 
clinicians should seriously consider initiating antiviral 
treatment as soon as possible. Such an approach may 
be life-saving, especially in settings devoid of rapid 
virological diagnostic services.   
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